Tel Aviv, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, announced today that Quantum Transportation Ltd. ("Quantum Transportation" or "QT"),- a minority-owned subsidiary of Quantum X Labs Ltd., the Israeli quantum tech group Viewbix is in the process of acquiring, has successfully achieved a key cloud implementation milestone in its transformer-based quantum decoder program. Following the successful initial validation of ...

Core Viewpoint - Helus Pharma has appointed Dr. Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, aiming to enhance its clinical development strategy and regulatory engagement for its novel serotonergic agonist portfolio [2][6]. Company Overview - Helus Pharma is a clinical stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) to address serious mental health conditions such as depression and anxiety [9][10]. - The company operates in Canada, the United States, the United Kingdom, and Ireland [11]. Leadership Appointment - Dr. Freda Lewis-Hall brings over 40 years of experience in clinical care, research, and corporate leadership, having previously served as Executive Vice President and Chief Medical Officer at Pfizer [3][4]. - Her role will involve providing leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities and clinical development strategies [6][7]. Clinical Development Focus - Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. FDA [10]. - HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder [10]. Strategic Goals - The company aims to improve the treatment landscape for mental health through its innovative NSAs, focusing on delivering meaningful outcomes for patients and long-term value for stakeholders [6][10].

Core Insights - North Media's Board of Directors has nominated Lasse Ingemann Brodt for election as a new member of the Board at the annual general meeting scheduled for 10 April 2026, with expectations for him to become the new chairman immediately after the meeting [1] - Lasse Ingemann Brodt has been part of North Media's Group Executive Board since 2018 and will join the Board as a non-independent member, which deviates from the Danish Recommendations on Corporate Governance [2] - Martin Frandsen Tobberup has been appointed as Group Executive Director effective 10 April 2026, contingent upon Brodt's election to the Board and his resignation as Group CEO [4] Leadership Changes - The leadership structure will include Lasse Ingemann Brodt as Chairman and Martin Frandsen Tobberup as Group Executive Director, enhancing the Group's commercial expertise and commitment to business development [6][7] - The Group Executive Board will consist of Martin Frandsen Tobberup, Lisbeth Britt Larsen (Group CHRO), and Ask Illum Jessen (Group CICO), with Christian Deichmann joining as Group CFO by 1 August 2026 [5] Company Overview - North Media operates platforms that connect businesses and consumers, focusing on transactions related to groceries, rental housing, and digital access management solutions [9] - The company has two core business areas: Last Mile, which includes FK Distribution and SDR Svensk Direktreklam, and Digital Services, which encompasses BoligPortal, Dayli (MineTilbud), and Bekey [10]

Core Insights - Paratek Pharmaceuticals announced positive top-line results from two animal studies supporting the development of NUZYRA for the treatment of pulmonary anthrax [1][3] - The studies involved a non-human primate model and a rabbit model, with the latter's data to be presented in Spring 2026 [1][3] - The positive findings have led to additional procurement of NUZYRA under the Project BioShield contract with BARDA [2][6] Group 1: Study Results - The NHP study data were previously presented at a conference, while pivotal rabbit study data will be shared at an upcoming conference [1] - These studies confirm NUZYRA's therapeutic efficacy in treating pulmonary anthrax, building on previous findings for post-exposure prophylaxis [3] Group 2: Contract and Procurement - The BARDA contract, valued at approximately $304 million, supports the development of NUZYRA and includes procurement of up to 10,000 treatment courses for anthrax [6] - Oral NUZYRA tablets associated with this procurement were produced in the U.S. as part of the company's onshoring initiative [2][6] Group 3: Company Overview - Paratek Pharmaceuticals focuses on developing specialty therapies for public health threats and unmet medical needs, with products including NUZYRA and XHANCE [5] - The company is privately held by B-FLEXION Life Sciences [5]

DAYTONA BEACH, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- TopBuild Corp. (NYSE:BLD), a leading installer of insulation and commercial roofing and a specialty distributor of insulation and related building products to the construction industry in the United States and Canada, announced it has entered into an agreement to acquire Johnson Roofing, one of the largest commercial roofing installation services companies in Texas with approximately $29 million in annual revenue. Founded in 1941 in Waco, Johnson Roofin ...

Action Bolsters Support for Customer Base While Cutting Annual Operating Expenses by Approximately $7.5 MillionCOLUMBIA, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rekor Systems, Inc. (NASDAQ: REKR) ("Rekor or the "Company"), a global leader in roadway intelligence, today announced a strategic consolidation of its worldwide engineering operations aimed at increasing operational efficiency and aligning the Company's cost structure with current revenue levels. As part of this initiative, Rekor will move engineeri ...

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rio Silver Inc. (“Rio Silver” or the “Company”) (TSX-V: RYO | OTC: RYOOF) is pleased to invite current and prospective investors to meet with management at the Prospectors & Developers Association of Canada (PDAC) Convention 2026, the foremost global mining and mineral exploration conference. The PDAC Convention 2026 will be held at the Metro Toronto Convention Centre, South Building, located at 222 Bremner Blvd, Toronto, Ontario. Rio Silver wil ...

GREENWICH, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Stardust Power Inc. (NASDAQ: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today announced that it has joined the Cornerstone Consortium, a U.S. Department of Defense aligned collaborative framework focused on strengthening the domestic industrial base and securing critical supply chains. The Cornerstone Consortium brings together a broad range of domestically held organizations, including the U.S. Dep ...

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [3] - The company's lead program, Zumilokibart (APG777), is being developed primarily for AD, which is identified as the largest and least penetrated market within I&I [3] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which target established mechanisms of action and utilize advanced antibody engineering [3] Upcoming Events - Management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 a.m. E.T. [1] - The company will also attend the UBS Biotech Summit Miami on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026 [1] Investor Relations - For investor inquiries, Noel Kurdi serves as the VP of Investor Relations at Apogee Therapeutics [4] - Media inquiries can be directed to Dan Budwick at 1AB [4]

Mainz Biomed to Present Industry Leading Results: 100% Sensitivity and 95% SpecificityBERKELEY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in Chicago, Illinois. At the conference the Company will present its poster titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA A ...